256 related articles for article (PubMed ID: 9405727)
21. Estimates of volumetric bone density from projectional measurements improve the discriminatory capability of dual X-ray absorptiometry.
Jergas M; Breitenseher M; Glüer CC; Yu W; Genant HK
J Bone Miner Res; 1995 Jul; 10(7):1101-10. PubMed ID: 7484286
[TBL] [Abstract][Full Text] [Related]
22. New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status.
Krege JH; Miller PD; Lenchik L; Misurski DA; Chen P
J Clin Densitom; 2006; 9(2):144-9. PubMed ID: 16785072
[TBL] [Abstract][Full Text] [Related]
23. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements.
Pitukcheewanont P; Safani D; Church J; Gilsanz V
Osteoporos Int; 2005 Nov; 16(11):1393-6. PubMed ID: 15702261
[TBL] [Abstract][Full Text] [Related]
24. Size-adjustment techniques of lumbar spine dual energy X-ray absorptiometry measurements in assessing bone mineralization in children on maintenance hemodialysis.
Salem N; Bakr A
J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1291-1302. PubMed ID: 34273916
[TBL] [Abstract][Full Text] [Related]
25. Peak bone mineral density, lean body mass and fractures.
Boot AM; de Ridder MA; van der Sluis IM; van Slobbe I; Krenning EP; Keizer-Schrama SM
Bone; 2010 Feb; 46(2):336-41. PubMed ID: 19833245
[TBL] [Abstract][Full Text] [Related]
26. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
Folkestad L
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
[TBL] [Abstract][Full Text] [Related]
27. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
28. The relationship between lean body mass and bone mineral content in paediatric health and disease.
Crabtree NJ; Kibirige MS; Fordham JN; Banks LM; Muntoni F; Chinn D; Boivin CM; Shaw NJ
Bone; 2004 Oct; 35(4):965-72. PubMed ID: 15454104
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
30. Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta.
Kocijan R; Muschitz C; Fratzl-Zelman N; Haschka J; Dimai HP; Trubrich A; Bittighofer C; Resch H
Skeletal Radiol; 2013 Feb; 42(2):187-94. PubMed ID: 22955449
[TBL] [Abstract][Full Text] [Related]
31. The interaction between Sillence type and BMD in osteogenesis imperfecta.
Kok DJ; Uiterwaal CS; Van Dongen AJ; Kramer PP; Pruijs HE; Engelbert RH; Verbout AJ; Schweitzer DH; Sakkers RJ
Calcif Tissue Int; 2003 Nov; 73(5):441-5. PubMed ID: 12958692
[TBL] [Abstract][Full Text] [Related]
32. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Zacharin M; Kanumakala S
J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
[TBL] [Abstract][Full Text] [Related]
33. Association of trabecular bone score and bone mineral apparent density with the severity of bone fragility in children and adolescents with osteogenesis imperfecta: A cross-sectional study.
Ohata Y; Kitaoka T; Ishimi T; Yamada C; Nakano Y; Yamamoto K; Takeyari S; Nakayama H; Fujiwara M; Kubota T; Ozono K
PLoS One; 2023; 18(8):e0290812. PubMed ID: 37643181
[TBL] [Abstract][Full Text] [Related]
34. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
35. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
36. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
37. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
38. Bone mineral content and collagen defects in osteogenesis imperfecta.
Lund AM; Mølgaard C; Müller J; Skovby F
Acta Paediatr; 1999 Oct; 88(10):1083-8. PubMed ID: 10565454
[TBL] [Abstract][Full Text] [Related]
39. Lumbar bone mineral density at final height and prevalence of fractures in treated children with GH deficiency.
Baroncelli GI; Bertelloni S; Sodini F; Saggese G
J Clin Endocrinol Metab; 2002 Aug; 87(8):3624-31. PubMed ID: 12161486
[TBL] [Abstract][Full Text] [Related]
40. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
